Nxera Pharma UK Limited
15
1
1
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
13.3%
2 terminated/withdrawn out of 15 trials
85.7%
-0.8% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
HTL0039732 in Participants With Advanced Solid Tumours
Role: collaborator
A Study in Healthy Subjects to Assess the Safety, Tolerability and Pharmacokinetics of HTL0022562
Role: lead
A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310
Role: lead
Comparison of Blood Levels of HTL0016878 From an Oral Capsule and an Oral Solution
Role: lead
Study to Investigate the Receptor Occupancy of HTL0014242 Using [18F] FPEB in Healthy Male Subjects
Role: lead
Phase 1, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of mGlu5 NAM HTL0014242
Role: lead
Measurement of HTL0016878 in Cerebrospinal Fluid
Role: lead
A Two Part Study to Assess Safety, PK, PD, and Food Effect of Oral HTL0016878
Role: lead
A Study to Assess Safety, Tolerability, and Efficacy of HTL0018318 in Patients With Dementia With Lewy Bodies
Role: lead
Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care
Role: lead
Pharmacokinetics of Oral Capsule in Healthy Japanese vs. Caucasian Subjects
Role: lead
Phase I, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of an M1 Agonist to Treat Cognitive Impairment
Role: lead
Relative Bioavailability of HTL0018318 Oral Aqueous Solution Versus Capsules
Role: lead
Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects
Role: lead
Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation
Role: lead
All 15 trials loaded